Financial Summary (All financials)
| In millions, except per share items | Mar-31-23 | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 |
| Revenues | 8,438.7 | 6,820.9 | 5,438.4 | 5,274.2 | 5,349.5 | 3,980.8 | 3,407.8 | 2,173.3 |
| Revenue growth | 23.7% | 25.4% | 3.1% | -1.4% | 34.4% | 16.8% | 56.8% | 1.2% |
| Cost of goods sold | 2,740.8 | 2,371.3 | 2,059.6 | 2,032.1 | 2,418.2 | 1,560.1 | 1,650.6 | 967.8 |
| Gross profit | 5,697.9 | 4,449.6 | 3,378.8 | 3,242.1 | 2,931.3 | 2,420.7 | 1,757.2 | 1,205.5 |
| Gross margin | 67.5% | 65.2% | 62.1% | 61.5% | 54.8% | 60.8% | 51.6% | 55.5% |
| Selling, general and administrative | 797.7 | 718.9 | 610.3 | 676.6 | 682.9 | 452.1 | 499.8 | 301.7 |
| Research and development | 1,118.3 | 989.1 | 836.4 | 877.8 | 826.3 | 529.3 | 545.3 | 372.6 |
| EBITA | 3,865.7 | 2,813.5 | 1,992.5 | 1,740.5 | 1,443.6 | 1,445.8 | 720.5 | 535.3 |
| EBITA margin | 45.8% | 41.2% | 36.6% | 33.0% | 27.0% | 36.3% | 21.1% | 24.6% |
| Amortization of intangibles | 753.7 | 934.4 | 992.7 | 1,046.7 | 695.8 | 492.2 | 346.3 | 179.3 |
| EBIT | 3,112.0 | 1,879.1 | 999.8 | 693.8 | 747.8 | 953.6 | 374.2 | 356.0 |
| EBIT margin | 36.9% | 27.5% | 18.4% | 13.2% | 14.0% | 24.0% | 11.0% | 16.4% |
| Pre-tax income | 2,909.7 | 1,482.5 | 339.5 | 150.4 | 204.5 | 737.3 | 89.8 | 281.3 |
| Income taxes | 672.0 | 197.0 | -9.9 | -420.2 | -151.4 | 481.9 | -80.8 | -42.6 |
| Tax rate | 23.1% | 13.3% | | | | 65.4% | | |
| Earnings from continuing ops | 2,237.7 | 1,285.5 | 349.4 | 570.6 | 355.9 | 255.4 | 170.6 | 324.1 |
| Earnings from discontinued ops | | | | | | | -6.0 | |
| Net income | 2,237.7 | 1,285.5 | 349.4 | 570.6 | 355.9 | 255.4 | 164.6 | 324.1 |
| Net margin | 26.5% | 18.8% | 6.4% | 10.8% | 6.7% | 6.4% | 4.8% | 14.9% |
| |
| Diluted EPS | $4.02 | $2.27 | $0.65 | $1.11 | $1.42 | $1.03 | $0.73 | $1.49 |
| Shares outstanding (diluted) | 557.3 | 565.9 | 541.2 | 512.4 | 249.9 | 248.9 | 234.8 | 217.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|